Cargando…
Combinations of Host- and Virus-Targeting Antiviral Drugs Confer Synergistic Suppression of SARS-CoV-2
Three directly acting antivirals (DAAs) demonstrated substantial reduction in COVID-19 hospitalizations and deaths in clinical trials. However, these agents did not completely prevent severe illness and are associated with cases of rebound illness and viral shedding. Combination regimens can enhance...
Autores principales: | Wagoner, Jessica, Herring, Shawn, Hsiang, Tien-Ying, Ianevski, Aleksandr, Biering, Scott B., Xu, Shuang, Hoffmann, Markus, Pöhlmann, Stefan, Gale, Michael, Aittokallio, Tero, Schiffer, Joshua T., White, Judith M., Polyak, Stephen J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society for Microbiology
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9718484/ https://www.ncbi.nlm.nih.gov/pubmed/36190406 http://dx.doi.org/10.1128/spectrum.03331-22 |
Ejemplares similares
-
Discovery of host-directed modulators of virus infection by probing the SARS-CoV-2–host protein–protein interaction network
por: Ravindran, Vandana, et al.
Publicado: (2022) -
Drug Combinations as a First Line of Defense against Coronaviruses and Other Emerging Viruses
por: White, Judith M., et al.
Publicado: (2021) -
SynergyFinder 2.0: visual analytics of multi-drug combination synergies
por: Ianevski, Aleksandr, et al.
Publicado: (2020) -
Fully-automated and ultra-fast cell-type identification using specific marker combinations from single-cell transcriptomic data
por: Ianevski, Aleksandr, et al.
Publicado: (2022) -
SynergyFinder 3.0: an interactive analysis and consensus interpretation of multi-drug synergies across multiple samples
por: Ianevski, Aleksandr, et al.
Publicado: (2022)